(IN BRIEF) AstraZeneca and Quell Therapeutics have announced a collaboration to develop innovative treatments for Type 1 Diabetes and Inflammatory Bowel Disease. Quell’s T-regulatory cell engineering technology will be used to create potential curative therapies. AstraZeneca has the option to … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, autoimmune disease, cell therapies, Foxp3 Phenotype Lock, Iain McGill, IBD, IND, inflammatory bowel disease, Investigational New Drug, Mene Pangalos, multi-modular Treg cell therapy, Quell, Quell Therapeutics, T-regulator, T-regulatory cell engineering, T1D, Treg, type 1 diabetes
London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that on 4 October MedImmune, its global biologics research and development arm, completed its acquisition of Amplimmune, a privately-held, US-based biologics company focused on developing novel therapeutics in cancer immunology. As previously announced, … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged acquisition, Amplimmune, Anthony Brown, anti-PD-L1 mAb, AstraZeneca, autoimmune disease, Ayesha Bharmal, biologics, Cancer, cancer cells, cancer immunology, co-inhibitory molecules, co-stimulatory molecules, Colleen Proctor, Ed Seage, Esra Erkal-Paler, Gaithersburg, immune system, immune-mediated cancer therapy, IMT-C, infectious disease, Jacob Lund, Jens Lindberg, Karl Hård, MEDI-4736, MedImmune, mOX40 mAb, therapeutics, Tracy Rossin, transplantation, tremelimumab
16-8-2013 — /EuropaWire/ — Immunologists at LMU have come up with a new technique that can be used both to fight tumors and to treat autoimmune diseases. A new grant from the Federal Ministry for Education and Research will enable the … Read the full press release
Posted in Education, Germany, Healthcare, Pharma & Biotech, Science
Tagged autoimmune disease, autoimmune diseases, BMBF, Clinical Neuroimmunology, Cytotoxic T cells, fight tumors, LMU, multiple sclerosis, pathogen-derived protein fragments, peptides, Privatdozent Dr. Klaus Dornmair, Prof. Jörg Prinz, psoriasis, T cells, treat autoimmune diseases, tumor-specific antigens, tumors, Validation of the Innovation Potential of Scientific Research
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
